Next Slideshow Title
National Psoriasis Foundation: “Can't sleep? Psoriasis, psoriatic arthritis may be to blame,” “Depression,” “Healing power of a protein could help psoriasis,” “Herbs/Natural Remedies,” “Link found between osteoporosis and psoriasis, psoriatic arthritis,” “Moderate to Severe Psoriasis and Psoriatic Arthritis: Biologic Drugs,” “The link between psoriatic disease and mental illness,” “Treat to Target,” “Trial drug shows small target can improve psoriasis.”
Journal of the American Academy of Dermatology: “From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.”
Nature Communications: “IL-12 protects from psoriasis from skin inflammation.”
The New England Journal of Medicine: “A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis,” “Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.”
News release, University of Zurich.
News release, Northwestern University Feinberg School of Medicine.
News release, FDA.
ClinicalTrials.gov: “BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis,” “Sleep, Circadian Rhythm & Skin Health.”
News release, Nasdaq.
Science: “Spherical RNA therapy shows promise against psoriasis in first human trial.”
Iranian Journal of Pharmaceutical Research: “Topical Turmeric Microemulgel in the Management of Plaque Psoriasis; A Clinical Evaluation.”
American College of Rheumatology: “Clinical Improvements in Psoriasis and Psoriatic Arthritis with Surgical Weight Loss.”
NYU Langone Medical Center: “Psoriasis & Psoriatic Arthritis Symptoms Curbed by Bariatric Surgery.”
JAMA Dermatology: “Psoriasis and the Risk of Depression in the US Population.”
Lancet: “Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.”
Psoriasis: Targets and Therapy: “Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability.”
The Biochemical Journal: “Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation.”
Arteriosclerosis, Thrombosis, and Vascular Biology : “Nationwide Study on the Risk of Abdominal Aortic Aneurysms in Patients With Psoriasis,” “Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study.”
Journal of Dermatology: “Psoriasis and bone mineral density: implications for long-term patients.”
Science Translational Medicine: “Chronic skin inflammation leads to bone loss by IL-17–mediated inhibition of Wnt signaling in osteoblasts.”
News release, Spanish National Cancer Research Centre.
The Journal of Clinical Investigation: “A GRHL3-regulated repair pathway suppresses immune-mediated epidermal hyperplasia,” “RAC1 activation drives pathologic interactions between the epidermis and immune cells.”
News release, Stanford Medicine.
Reviewed by Stephanie S. Gardner, MD on October 22, 2019
This tool does not provide medical advice. See additional information.
THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.